Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

The antifungal efficacy, safety, and pharmacokinetics of posaconazole (SCH 56592) (POC) were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Antifungal therapy consisted of POC at 2, 6, and 20 mg/kg of bod...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Petraitiene, Ruta, Petraitis, Vidmantas, Groll, Andreas H., Sein, Tin, Piscitelli, Stephen, Candelario, Myrna, Field-Ridley, Aida, Avila, Nilo, Bacher, John, Walsh, Thomas J.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2001
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC90385/
https://ncbi.nlm.nih.gov/pubmed/11181372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.45.3.857-869.2001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars